ProvexisCHIX:PXSL Market Cap is £29.32 Mil as of Jun. 29, 2026. The stock has 1 warning sign investors should review. Among 1,020 Drug Manufacturers companies, Provexis ranks worse than 71.18% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Provexis's share price for the quarter that ended in Sep. 2025 was £0.0074. Provexis's Shares Outstanding (EOP) for the quarter that ended in Sep. 2025 was 2,345.89 Mil. Therefore, Provexis's market cap for the quarter that ended in Sep. 2025 was £17.36 Mil.
Provexis's quarterly market cap
stayed the same
from Sep. 2024 (£0.00 Mil) to Mar. 2025 (£0.00 Mil) but then
increased
from Mar. 2025 (£0.00 Mil) to Sep. 2025 (£17.36 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Provexis's Enterprise Value for Today is £28.27 Mil.
Provexis (CHIX:PXSl) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Provexis Market Cap Related Terms
Provexis Market Cap Historical Data
* Premium members only.
The historical data trend for Provexis's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:PXSL vs ZTS, UTHR, VTRS: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Provexis's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Provexis Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Provexis's Market Cap distribution charts can be found below:
* The bar in red indicates where Provexis's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Provexis's Market Cap for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Provexis (CHIX:PXSL) has a Market Cap of £29.32 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Provexis and its competitors. According to the industry distribution chart, Provexis ranks #726 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 71.2%.
Is Provexis' Market Cap too high?
Provexis' current Market Cap is £29.32 Mil. Based on the distribution chart, Provexis ranks #726 out of 1020 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Provexis' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Provexis ranks #726 out of 1020 companies for Market Cap. This places Provexis in the lower half of its industry. The industry median Market Cap is 206.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 206.61, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Provexis and its competitors. For the Drug Manufacturers industry, the median Market Cap is 206.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Provexis's current Market Cap is £29.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provexis stock overvalued right now?
Provexis (CHIX:PXSL) has a current Market Cap of £29.32 Mil. The current Market Cap is £29.32 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Provexis (CHIX:PXSL), the current Market Cap is £29.32 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Provexis PLC is engaged in developing, licensing and selling the proprietary, scientific Fruitflow heart-health functional food ingredient for the global functional food sector. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:PXSL has been successfully added to your 